OHR Pharmaceutical, Inc. (OHRP) Declined to $2.28

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) Corporate Logo

Big Money Sentiment decreased to 0.5 in 2018 Q4. It has change of 0.50, from 2018Q3’s 1. The ratio worsened due to OHR Pharmaceutical, Inc. positioning: 4 sold and 8 reduced. 3 funds bought positions and 3 increased positions. Investors holded 5.29 million in 2018Q3 but now own 4.23 million shares or 20.01% less.
Morgan Stanley holds 4,872 shs or 0% of its capital. Bryn Mawr Tru has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Geode Capital Management Lc invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Citadel Advisors Limited has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Blackrock accumulated 414,868 shs or 0% of the stock. Leisure Cap Management holds 0% or 57,921 shs. California Pub Employees Retirement Systems holds 78,800 shs. Retail Bank Of America Corporation De stated it has 500 shs. Paloma Prns Mngmt owns 76,400 shs or 0% of their US capital. Garrison Bradford And Associate invested in 0.01% or 101,000 shs. Huntington Comml Bank owns 1 shs for 0% of their capital. Northern Trust holds 0% or 135,564 shs in its capital. Creative Planning holds 68,000 shs or 0% of its capital. The New York-based Bank Of Mellon has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Renaissance Technologies Ltd Liability Corp accumulated 1.98 million shs.

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) decreased to $2.28. On Mar, 11 the move was reported by Barchart.com. It has $6.45M market cap. The company’s valuation will be $387,060 less at $2.14 price target.

For more OHR Pharmaceutical, Inc. (NASDAQ:OHRP) news released briefly go to: Benzinga.com, Benzinga.com, Benzinga.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal – Benzinga” released on February 15, 2019, “35 Stocks Moving In Monday’s Mid-Day Session – Benzinga” on February 11, 2019, “51 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” with a publish date: March 07, 2019, “Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019 – GlobeNewswire” and the last “Bragar Eagel & Squire, PC is Investigating the Board of Directors of OHR Pharmaceutical, Inc. (OHRP) on Behalf of Stockholders and Encourages OHRP Investors to Contact the Firm – GlobeNewswire” with publication date: January 04, 2019.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease.The firm is valued at $6.45 million. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.Last it reported negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.